TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30978179

Group type: EXPERIMENTAL
Intervention: Community-Level Interventions for Pre-eclampsia (CLIP) intervention with supplementary hypertension-oriented care and standardised blood pressure measurement.
Number of subjects: 28420

Group type: EXPERIMENTAL
Intervention: Gestational hypertension diagnosis at first presentation with elevated BP.
Number of subjects: 28420

Group type: EXPERIMENTAL
Intervention: Pre-eclampsia diagnosis.
Number of subjects: 28420

Group type: EXPERIMENTAL
Intervention: Chronic hypertension diagnosis.
Number of subjects: 28420

Group type: EXPERIMENTAL
Intervention: Inclusion of additional diagnoses of hypertension and related complications from household surveys or facility record review.
Number of subjects: 28420
Study: 30978404

Group type: EXPERIMENTAL
Intervention: Epicutaneous immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30978502

Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 34
Study: 30978536

Group type: EXPERIMENTAL
Intervention: Bismuth salts (240 mg) combined with proton pump inhibitors (esomeprazole, omeprazole, pantoprazole, rabeprazole), amoxicillin (1 g), and clarithromycin (500 mg), all taken twice daily for 14 days.
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Bismuth salts (240 mg) combined with standard triple therapy.
Number of subjects: 1141

Group type: COMPARATOR
Intervention: Standard triple therapy without bismuth (not explicitly mentioned in the abstract).
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Bismuth salts with a double dose of proton pump inhibitor (equivalent to 40 mg omeprazole).
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: 14-day duration of treatment.
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Treatment compliance.
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: Adverse events occurred in 36% of patients; 76% of these events were mild, with a mean duration of 6 days.
Number of subjects: 1141
Study: 30979361

Group type: EXPERIMENTAL
Intervention: Surprise Question (SQ) response [Yes/No]
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Alternative Surprise Question response [Yes/No]
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Percentage probability of dying [0% - 100%]
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Proposed treatment plan [multiple choice]
Number of subjects: 600
Study: 30979546

Group type: EXPERIMENTAL
Intervention: Respiratory support
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Invasive ventilator-free survival
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Vitamin B6-dependent seizures and respiratory distress/failure
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase activity
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Chest deformity, respiratory distress, respiratory failure, failure to thrive, elevated calcium levels
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 48
Study: 30979737

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 71
Study: 30979811

Group type: EXPERIMENTAL
Intervention: Preterm delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low birth weight (LBW) (<2500 g)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small for gestational age (SGA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early-term delivery
Number of subjects: 0
Study: 30979843

Group type: EXPERIMENTAL
Intervention: Deleterious somatic variants in OC predisposition genes
Number of subjects: 473
Study: 30979860

Group type: EXPERIMENTAL
Intervention: FSHD1
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: FSHD2
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Overlap between FSHD1 and FSHD2
Number of subjects: 103
Study: 30980071

Group type: EXPERIMENTAL
Intervention: Crizotinib (250 mg twice daily)
Number of subjects: 53
Study: 30980576

Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir + dasabuvir with low-dose ribavirin for 12 weeks
Number of subjects: 105
Study: 30980734

Group type: EXPERIMENTAL
Intervention: Fostemsavir (FTR) 600 mg twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (without Fostemsavir)
Number of subjects: 32
Study: 30980827

Group type: EXPERIMENTAL
Intervention: Etonogestrel contraceptive implants
Number of subjects: 350
Study: 30981000

Group type: EXPERIMENTAL
Intervention: Patients with IBD
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patients with ulcerative colitis
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy individuals (controls)
Number of subjects: 32
Study: 30981008

Group type: EXPERIMENTAL
Intervention: MINI index scores below 8 in the derivation cohort
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: MINI index scores below 8 in the validation cohort
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: MINI index scores of 8 or more in the validation cohort
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: MINI index scores below 8
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: MINI index scores below 6
Number of subjects: 322

Group type: COMPARATOR
Intervention: Measurement of fecal calprotectin
Number of subjects: 322
Study: 30981280

Group type: EXPERIMENTAL
Intervention: Short-term ureteral stenting (3-6 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ureteral stent biofilms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bacterial communities in biofilms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of extracellular DNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ureteral stent biofilms in patients with Enterobacterales and Corynebacterium-dominated microbiomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Classification of patients according to different urotypes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facultative pathogens
Number of subjects: 0
Study: 30981574

Group type: EXPERIMENTAL
Intervention: Patients with high-risk features (n=5323)
Number of subjects: 10236

Group type: COMPARATOR
Intervention: Patients without high-risk features
Number of subjects: 10236

Group type: EXPERIMENTAL
Intervention: Patients with increasing number of high-risk features (0, 1-2, ≥3)
Number of subjects: 10236

Group type: EXPERIMENTAL
Intervention: Patients with high-PRECISE-DAPT score (≥25)
Number of subjects: 10236
Study: 30981717

Group type: EXPERIMENTAL
Intervention: 3-dimensional introital ultrasound imaging
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: 3-dimensional transperineal ultrasound imaging
Number of subjects: 250

Group type: COMPARATOR
Intervention: Endoanal ultrasound imaging
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Introital and transperineal ultrasound imaging
Number of subjects: 250
Study: 30981722

Group type: EXPERIMENTAL
Intervention: Normal mobility on presentation and first recorded NEWS < 3
Number of subjects: 3363

Group type: EXPERIMENTAL
Intervention: IMOP and NEWS ≥ 3 when first recorded
Number of subjects: 3363

Group type: EXPERIMENTAL
Intervention: IMOP
Number of subjects: 3363

Group type: EXPERIMENTAL
Intervention: NEWS ≥ 3 when first recorded
Number of subjects: 3363
Study: 30981783

Group type: EXPERIMENTAL
Intervention: Lentiviral vector-derived gene therapy
Number of subjects: 8
Study: 30981956

Group type: EXPERIMENTAL
Intervention: Regular long naps
Number of subjects: 4170

Group type: COMPARATOR
Intervention: Regular short naps, irregular naps, or no naps
Number of subjects: 4170
Study: 30981987

Group type: EXPERIMENTAL
Intervention: Plasma ctDNA analysis
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: ctDNA assay
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: ctDNA assay for lung cancer stages
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Combination of ctDNA, patient age, and serum biomarkers
Number of subjects: 192
Study: 30982000

Group type: EXPERIMENTAL
Intervention: All-site screening for CT/NG infections
Number of subjects: 764

Group type: EXPERIMENTAL
Intervention: Rectal screening
Number of subjects: 764

Group type: COMPARATOR
Intervention: Single anatomical site testing
Number of subjects: 764

Group type: COMPARATOR
Intervention: Pharyngeal site testing
Number of subjects: 764

Group type: COMPARATOR
Intervention: Rectal site testing
Number of subjects: 764

Group type: COMPARATOR
Intervention: Urethral site testing
Number of subjects: 764
Study: 30982564

Group type: EXPERIMENTAL
Intervention: Intraoperative low-dose fentanyl (about 60-120 μg for a 70 kg patient)
Number of subjects: 145735

Group type: COMPARATOR
Intervention: High intraoperative fentanyl doses (median: 3.85; IQR: 3.42-4.50 μg kg)
Number of subjects: 145735

Group type: COMPARATOR
Intervention: No fentanyl
Number of subjects: 145735
Study: 30982671

Group type: EXPERIMENTAL
Intervention: Same-day strategy (hour h, h+1, h+2)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conventional strategy (sputum collection on three consecutive days)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Both strategies
Number of subjects: 131
Study: 30982856

Group type: EXPERIMENTAL
Intervention: Mother's own milk (MOM), n = 74, average 91% MOM in enteral feeds.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Donor breast milk (DM), n = 43, average 14% MOM in enteral feeds.
Number of subjects: 125
Study: 30983543

Group type: EXPERIMENTAL
Intervention: Intestinal glucose load
Number of subjects: 0
Study: 30984044

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30984354

Group type: EXPERIMENTAL
Intervention: Daily walnut intake (45 g for 16 weeks)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Iso-caloric white bread (control)
Number of subjects: 119
Study: 30984405

Group type: EXPERIMENTAL
Intervention: Community-based lifestyle behavior intervention study
Number of subjects: 569
Study: 30984879

Group type: EXPERIMENTAL
Intervention: Interventional bundle to reduce mortality from gastroschisis
Number of subjects: 0
Study: 30984970

Group type: EXPERIMENTAL
Intervention: High systolic home BP variability
Number of subjects: 75

Group type: COMPARATOR
Intervention: Low systolic home BP variability
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Home BP variability
Number of subjects: 75
Study: 30985279

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost treatment via the Breelib nebulizer for 3 months ± 2 weeks, in addition to existing PAH therapy.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost treatment via the Breelib nebulizer.
Number of subjects: 80
Study: 30985286

Group type: EXPERIMENTAL
Intervention: Remote monitoring in addition to prenatal follow-up
Number of subjects: 91
Study: 30985369

Group type: EXPERIMENTAL
Intervention: Autologous fat transfer (AFT); average volume: 23.9 ± 13.2 mL
Number of subjects: 20
Study: 30985509

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 605

Group type: COMPARATOR
Intervention: Standard indications (SI)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Complex medical disorders
Number of subjects: 605

Group type: COMPARATOR
Intervention: NMD vs SI
Number of subjects: 605

Group type: COMPARATOR
Intervention: NMD vs Complex medical disorders
Number of subjects: 605

Group type: COMPARATOR
Intervention: Severe infantile onset NMD vs general hypotonic disorders
Number of subjects: 605
Study: 30986359

Group type: EXPERIMENTAL
Intervention: Bridge-enhanced ACL repair with extracellular matrix scaffold
Number of subjects: 62
Study: 30986523

Group type: EXPERIMENTAL
Intervention: Inappropriate empirical antibiotic therapy (IEAT)
Number of subjects: 729

Group type: COMPARATOR
Intervention: Healthcare-associated infection (HCAI)
Number of subjects: 729

Group type: COMPARATOR
Intervention: Hospital-acquired infection (HAI)
Number of subjects: 729

Group type: EXPERIMENTAL
Intervention: Inappropriate empirical antibiotic therapy (IEAT) in bloodstream infections
Number of subjects: 729
Study: 30986548

Group type: EXPERIMENTAL
Intervention: Housing instability
Number of subjects: 340
Study: 30986735

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 591052

Group type: EXPERIMENTAL
Intervention: Mood stabilizing anticonvulsants (MSAs)
Number of subjects: 591052

Group type: EXPERIMENTAL
Intervention: Antipsychotics
Number of subjects: 591052

Group type: EXPERIMENTAL
Intervention: Monoamine oxidase inhibitors (MAOIs)
Number of subjects: 591052

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 591052

Group type: EXPERIMENTAL
Intervention: Polypharmacy (combination of drugs)
Number of subjects: 591052

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 591052
Study: 30986750

Group type: EXPERIMENTAL
Intervention: Prehospital statins
Number of subjects: 6523

Group type: COMPARATOR
Intervention: No prehospital statins (Control)
Number of subjects: 6523

Group type: EXPERIMENTAL
Intervention: Statin therapy at discharge
Number of subjects: 6523

Group type: EXPERIMENTAL
Intervention: Moderate doses of statins at discharge
Number of subjects: 6523
Study: 30987448

Group type: EXPERIMENTAL
Intervention: Patients with CCM having TTN truncating variants (TTNtvs)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Patients with CCM with TTNtvs
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Anthracycline-treated TTNtv mice and isolated TTNtv cardiomyocytes
Number of subjects: 213
Study: 30987597

Group type: EXPERIMENTAL
Intervention: 150 ml albumin 5% administered over 1 min in three consecutive 50-ml fluid boluses, followed by an additional 350 ml infused at a constant rate over 15 min (total 500 ml)
Number of subjects: 50
Study: 30988080

Group type: EXPERIMENTAL
Intervention: High-dose lapatinib (1,500 mg BID)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intermittent high-dose lapatinib alternating with capecitabine
Number of subjects: 11
Study: 30988172

Group type: EXPERIMENTAL
Intervention: hs-cTnI Access assay measured at presentation and at 1 hour
Number of subjects: 1579

Group type: COMPARATOR
Intervention: hs-cTnI Architect assay
Number of subjects: 1579
Study: 30988677

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30989318

Group type: EXPERIMENTAL
Intervention: suPAR levels in the highest quartile
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: suPAR levels
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: suPAR
Number of subjects: 1314

Group type: COMPARATOR
Intervention: GRACE score
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: Addition of suPAR to GRACE score
Number of subjects: 1314
Study: 30989436

Group type: EXPERIMENTAL
Intervention: Various anti-glioblastoma agents including temozolomide, carmustine, lomustine, procarbazine, irinotecan, cediranib, erlotinib, 5-fluorouracil, vincristine, dichloroacetate, IDH1 inhibitor ivosidenib; treatment duration: 3 or 6 days
Number of subjects: 6

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 6
Study: 30990523

Group type: EXPERIMENTAL
Intervention: 10% IV infusion of glucose during exercise
Number of subjects: 2

Group type: COMPARATOR
Intervention: Healthy persons
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Patient 1 (male, 26 years old)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Patient 2 (female, 15 years old)
Number of subjects: 2
Study: 30991108

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30991107

Group type: EXPERIMENTAL
Intervention: Elevated GLP-1 levels at 24 hours
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Persistently elevated GLP-1 levels at day 14
Number of subjects: 157

Group type: COMPARATOR
Intervention: Overall inpatient mortality
Number of subjects: 157

Group type: COMPARATOR
Intervention: Post-discharge 6-month mortality
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: GLP-1 and IL-6 levels
Number of subjects: 157

Group type: COMPARATOR
Intervention: Early death (<14 days)
Number of subjects: 157
Study: 30991623

Group type: EXPERIMENTAL
Intervention: Neurovascular biomarkers in T2DM patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALFF-CBF in left hippocampus and fractional ALFF-CBF in left amygdala
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ALFF-CBF in right fusiform gyrus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disease severity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Duration of T2DM
Number of subjects: 0
Study: 30991692

Group type: EXPERIMENTAL
Intervention: Circulating tumor cells (CTCs)
Number of subjects: 34
Study: 30991823

Group type: EXPERIMENTAL
Intervention: Adaptive Cardiac Resynchronization Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30991908

Group type: EXPERIMENTAL
Intervention: Psychoeducation plus automated text messaging intervention (iTAB-CV) for 2 months
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Psychoeducation plus automated text messaging intervention (iTAB-CV)
Number of subjects: 38
Study: 30991949

Group type: EXPERIMENTAL
Intervention: Automated ultrasound spinal landmark identification technique
Number of subjects: 100
Study: 30991972

Group type: EXPERIMENTAL
Intervention: 8-week habit-focused intervention (telecoaching and face-to-face sessions)
Number of subjects: 24
Study: 30991992

Group type: EXPERIMENTAL
Intervention: Micafungin (50 mg intravenously once daily during first induction chemotherapy)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Micafungin
Number of subjects: 65
Study: 30992008

Group type: EXPERIMENTAL
Intervention: Visit-to-visit fasting plasma glucose (FPG) variability (measured by coefficient of variation, CV-FPG)
Number of subjects: 455
Study: 30992054

Group type: EXPERIMENTAL
Intervention: Regional P-V curves derived from electrical impedance tomography (EIT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Global P-V curves (PVg)
Number of subjects: 12
Study: 30992268

Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG) 150 mg daily for 24 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Eltrombopag (EPAG) 150 mg daily
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined long-term data from both studies
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Targeted deep sequencing/whole-exome sequencing pre-EPAG and at primary response end point
Number of subjects: 40
Study: 30993165

Group type: EXPERIMENTAL
Intervention: Digital cholangioscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Occlusion cholangiogram
Number of subjects: 0
Study: 30993521

Group type: EXPERIMENTAL
Intervention: Less invasive unilateral posterolateral disc space debridement, supplemented by ipsilateral titanium cage implantation and pedicle screw fixation plus contralateral transfascial pedicle screw fixation
Number of subjects: 20
Study: 30994466

Group type: EXPERIMENTAL
Intervention: Dignity Therapy (DT) led by nurses or chaplains
Number of subjects: 560

Group type: COMPARATOR
Intervention: Usual outpatient palliative care
Number of subjects: 560
Study: 30994471

Group type: EXPERIMENTAL
Intervention: PrEveCOPD computer application
Number of subjects: 0
Study: 30994825

Group type: EXPERIMENTAL
Intervention: Dual anti-platelet therapy (DAPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 30994826

Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal medical treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventional treatment
Number of subjects: 0
Study: 30995146

Group type: EXPERIMENTAL
Intervention: Anti-clot treatment scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment satisfaction questionnaire for medication version II
Number of subjects: 0
Study: 30995208

Group type: EXPERIMENTAL
Intervention: Vancomycin 15 mg·kg infused over 1 hour, repeated every 12 hours
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cefazolin 30 mg·kg infused over 10 minutes, repeated every 4 hours
Number of subjects: 20
Study: 30995331

Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Number of subjects: 300
Study: 30995372

Group type: EXPERIMENTAL
Intervention: Lentiviral vector gene therapy combined with low-dose busulfan conditioning
Number of subjects: 8
Study: 30995373

Group type: EXPERIMENTAL
Intervention: UB-421 (10 mg/kg weekly)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: UB-421 (25 mg/kg every 2 weeks)
Number of subjects: 29
Study: 30996012

Group type: EXPERIMENTAL
Intervention: Selinexor 60 mg orally twice weekly on days 1 and 3 of each week, three of each 4-week cycle
Number of subjects: 10
Study: 30997117

Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg
Number of subjects: 40
Study: 30997151

Group type: EXPERIMENTAL
Intervention: Abatacept plus methotrexate
Number of subjects: 124

Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 124

Group type: COMPARATOR
Intervention: Abatacept
Number of subjects: 124
Study: 30997507

Group type: EXPERIMENTAL
Intervention: Low Energy Density (LED) preload (33 kcal/100 g)
Number of subjects: 31

Group type: COMPARATOR
Intervention: High Energy Density (HED) preload (97.9 kcal/100 g)
Number of subjects: 31
Study: 30997633

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: NOL index
Number of subjects: 26
Study: 30998220

Group type: EXPERIMENTAL
Intervention: Text messaging (SMS)-based distance learning program
Number of subjects: 48
Study: 30998393

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent implantation in African American women (AA)
Number of subjects: 1863

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent implantation in Hispanic/Latina women (HL)
Number of subjects: 1863

Group type: COMPARATOR
Intervention: White women (reference group)
Number of subjects: 1863
Study: 30998529

Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calorie Restriction (CR) followed with exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 0
Study: 30998789

Group type: EXPERIMENTAL
Intervention: TDF with or without 3TC or FTC (n = 489)
Number of subjects: 1419

Group type: COMPARATOR
Intervention: 3TC or FTC only (n = 150)
Number of subjects: 1419

Group type: EXPERIMENTAL
Intervention: 3TC or FTC as first line followed by adding/switching to TDF as second line (n = 780)
Number of subjects: 1419
Study: 30999262

Group type: EXPERIMENTAL
Intervention: Online social intelligence training (SIT) program
Number of subjects: 230

Group type: COMPARATOR
Intervention: Attention-control (AC) condition
Number of subjects: 230
Study: 30999906

Group type: EXPERIMENTAL
Intervention: Erythritol candies
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Xylitol candies
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (sorbitol) candies
Number of subjects: 90